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ABSTRACT An antibody generated to an a-keto amide
containing hapten 1 catalyzes the cis-trans isomerization of
peptidyl-prolyl amide bonds in peptides and in the protein
RNase T1. The antibody-catalyzed peptide isomerization re-
action showed saturation kinetics for the cis-substrate, Suc-
Ala-Ala-Pro-Phe-pNA, with a kcatyKm value of 883 s21zM21;
the reaction was inhibited by the hapten analog 13 (Ki 5 3.0 6
0.4 mM). Refolding of denatured RNase T1 to its native
conformation also was catalyzed by the antibody, with the
antibody-catalyzed folding reaction inhibitable both by the
hapten 1 and hapten analog 13. These results demonstrate
that antibodies can catalyze conformational changes in pro-
tein structure, a transformation involved in many cellular
processes.
The rate-limiting step in the slow folding reactions of many
proteins involves cis-trans isomerization about peptidyl-prolyl
amide bonds (1). The assistance of peptidyl-prolyl cis-trans
isomerization catalysts (rotamases) in the folding of several
proteins, including type III collagen (2), mouse Ig light chain
(3), RNase T1 (4), RNase A (5), staphylococcal nuclease (6),
creatine kinase (7), and cytochrome c (8), has been reported
along with several in vivo examples (9, 10). Rotamases also
have been proposed to play important physiological roles in
signal transduction. The isomerases cyclophilin (cyclosporin-
binding proteins) (11) and FKBP (FK506yrapamycin-binding
proteins) (12) suppress T cell activation by inhibiting cal-
cineurin (13); the recently identified mitotic Pin1 (14) regu-
lates mitotic progression by catalyzing sequence-specific and
phosphorylation-dependent proline isomerization (15). The
biological importance of peptidyl-prolyl isomerization, as well
as other protein conformational changes associated with pro-
tein folding and signal transduction, have led us to develop
antibody catalysts for this class of transformations. Such
catalysts might provide insights into the mechanisms of these
novel enzymatic reactions as well as tools for controlling
protein function in vitro and in vivo.
The cis-trans isomerization of the prolyl amide bond can
occur either by noncovalent stabilization of a twisted amide
(16, 17) or by tetrahedral adduct formation involving an active
site nucleophile (18, 19). In the case of Pin1, the participation
of an active site cysteine residue during peptide bond isomer-
ization is supported by crystallographic, pH titration, and
mutagenesis studies (20). In contrast, structural and mutagen-
esis studies of cyclophilins and FKBP have ruled out mecha-
nisms involving covalent catalysis (21). The crystal structures
of FK506 and the FK506-FKBP complex show that the N,N-
disubstituted a-keto amide group in FK506 exists in a non-
planar conformation. This observation has led to the sugges-
tion that the a-keto amide is a surrogate for the twisted amide
bond of a bound peptide substrate, consistent with a mecha-
nism involving substrate strain (22, 23).
In principle, an antibody generated against an a-keto amide
containing hapten might catalyze proline isomerization by
either of the above mechanisms. The a-keto amide group of
hapten 1, like that in FK506, presumably exists in an orthog-
onal conformation, because of allylic [A(1,3)] strain (22, 23). In
addition, the a-keto amide functionality in 1 contains an
electrophilic carbonyl group that might elicit an active site
nucleophile in the antibody combining site capable of forming
a tetrahedral adduct. The electrophilicity of the ketone car-
bonyl moiety in a-keto amides, acids, and esters is well
precedented (24); a crystal structure of trypsin complexed with
the ketoacid (4-amidinophenyl)pyruvate revealed that the
active site residue Ser-195 adds into the ketone carbonyl group
to form a tetrahedral adduct (25). Indeed, it has been shown
recently by Yli-Kauhaluoma et al. (26) that antibodies elicited
against a keto amide containing tripeptide catalyze the cis-
trans prolyl isomerization of the corresponding substrate with
kcatyKm values of 170–1,100 s21zM21. Here we report that
antibodies elicited against hapten 1 not only catalyze prolyl
isomerization in a peptide but also the proline isomerization-
dependent folding of RNase T1.
MATERIALS AND METHODS
Hapten Synthesis. (4S,5R)-N-tert-butyloxycarbonyl)-4-
methyl-5-carboxy-2-oxazolidinone (4). Dimethylaminopyridine
(DMAP; 4.7 g, 3.8 mmol), di-tert-butyl pyrocarbonate (3.6 g,
3 mmol), and triethylamine (3.2 ml, 2.3 mmol) were added to
a solution of (4S,5R)-(2)-4-methyl-5-phenyl-2-oxazolidinone
3 (3.4 g, 19.2 mmol) in 35 ml of tetrahydrofuran (THF). The
mixture was stirred at room temperature for 1 h after which
time more di-tert-butyl pyrocarbonate (4.5 g, 3.8 mmol) was
added. Stirring was continued for 2 h until analysis by TLC
indicated complete conversion of the starting material. The
solvent was evaporated, and the resulting oily residue was
redissolved in methylene chloride (150 ml) and washed with 1.0
N aqueous HCl (3 3 80 ml) and brine (80 ml). The organic
layer was concentrated and dried to afford 5.18 g (97%) of a
white solid: Rf 5 0.65 [50% (volyvol) EtOAc in hexane]; mp
97–98°C. The Boc-protected oxazolidinone was dissolved with-
out further purification in 40 ml of MeCN, 40 ml of CCl4, and
60 ml of water. Sodium periodate (64.16 g, 0.3 mol) was added
to this solution followed by 83 mg of ruthenium (III) chloride
hydrate (RuCl3z3H2O). The mixture was stirred vigorously at
room temperature for 24 h, after which time another 2.5
equivalents of periodate (10.7 g, 0.05 mol) and 1 mol%
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RuCl3z3H2O (41.5 mg, 0.2 mmol) were added. After an
additional 48 h, the solvent was evaporated, and the residue
was partitioned between EtOAc (250 ml) and brine (50 ml).
The organic layer was dried and concentrated to afford 6.4 g
of a black oil. The crude material was applied to a silica column
and eluted with 10% EtOAc in hexane. The fractions contain-
ing pure product were combined, concentrated, and dried
under high vacuum overnight to afford 2.31 g (48%) of a white
solid: Rf 5 0.12 (EtOAc); mp 117°C (dec); 1H NMR (400 MHz,
CDCl3) d 1.41 ppm (d, 3H, J 5 6.5 Hz), 1.56 (s, 9H), 4.55 (q,
1H, J 5 6.5 Hz), 5.05 (d, 1H, J 5 7.3 Hz), 6.10 (br s, 1H); 13C
NMR (125.7 MHz, CDCl3) d 14.91 ppm, 27.95, 52.72, 73.76,
84.74, 148.76, 150.49, 168.65; mass spectrum (FAB1) myz 246
(MH1). Exact mass calculated for C10H15NO6 was 246.0978;
found was 246.0977.
(2R,3S)-methyl-N-(tert-butyloxycarbonyl)-2-hydroxy-3-
aminobutanoate (6). Carboxylic acid 4 was converted quanti-
tatively to its methyl ester (5) by using diazomethane. Cesium
carbonate (0.66 g, 2.0 mmol) was added to a solution of ester
5 (2.40 g, 9.28 mmol) in MeOH (150 ml). The reaction mixture
was stirred at room temperature for 3 h, neutralized with citric
acid, and concentrated in vacuo. The resulting residue was
dissolved in EtOAc (250 ml) and washed with brine (125 ml).
The aqueous layer was extracted further with EtOAc (2 3 80
ml), and the organic layers were combined, dried over MgSO4,
and concentrated in vacuo to afford 1.9 g of a white solid. The
crude material was purified by flash chromatography on silica
gel and eluted with a gradient of 6:1 to 3:1 (volyvol) hexaney
EtOAc. The fractions containing pure product were com-
bined, concentrated, and dried to afford the methyl aminobu-
tanoate (1.18 g of a white solid), which was saponified with 1.0
N NaOH to provide aminobutanoic acid 6 (0.99 g, 91%) as a
white solid: Rf 5 0.09 (1:2 hexaneyEtOAc); mp 104°C (dec); 1H
NMR (400 MHz, CD3OD) d 1.06 ppm (d, 3H, J 5 6.9 Hz), 1.43
(s, 9H), 3.96–4.01 (m, 1H), 4.18–4.21 (m, 1H); 13C NMR
(100.6 MHz, CD3OD) d 14.71 ppm, 28.73, 49.95, 73.86, 80.16,
157.37, 175.87; mass spectrum (FAB1) myz 220 (MH1). Exact
mass calculated for C9H18NO5 was 220.1185; found was
220.1187.
L-prolyl-L-phenylalanyl-p-nitroanilide, trifluoroacetate salt
(8). N-(tert-butyloxycarbonyl)-L-proline (0.86 g, 4.0 mmol),
L-phenylalanine-p-nitroanilide (1.13 g, 4 mmol), and 1-hy-
droxybenzotriazole hydrate (HOBT, 0.56 g, 4.2 mmol) were
dissolved in dimethylformamide (DMF, 20 ml). The reaction
mixture was cooled to 4°C before 1-(3-dimethylaminopropyl)-
3-ethylcarbodiimide hydrochloride (EDC, 1.30 g, 6.7 mmol)
was added in three batches. The mixture was left overnight to
warm to room temperature and was concentrated in vacuo.
The residue was redissolved in methylene chloride (75 ml),
successively washed with saturated NaHCO3 (2 3 30 ml),
water (30 ml), 1.0 M citrate (pH 4.0, 2 3 30 ml), and brine (30
ml). The organic phase was dried over MgSO4 and concen-
trated in vacuo. Purification by flash chromatography on silica
gel using a gradient of 6:1 to 1:4 (volyvol) hexaneyEtOAc
afforded 1.72 g (89%) of Boc-Pro-Phe-pNA as a white foam.
Deprotection of Boc-Pro-Phe-pNA with trif luoroacetic acid
(TFA) gave 1.73 g (98%) of the desired salt (8) as a white solid:
Rf 5 0.07 (1:2 hexaneyEtOAc); mp 226°C (dec.); 1H NMR (400
MHz, CD3OD) d 1.94–2.13 ppm (m, 3H), 2.40–2.49 (m, 1H),
3.04 (dd, 1H, J 5 13.7 Hz, 8.6 Hz), 3.19 (dd, 1H, J 5 13.7 Hz,
6.7 Hz), 3.25–3.40 (m, 2H), 4.27 (dd, 1H, J 5 8.6 Hz, 6.7 Hz),
4.78 (dd, 1H, J 5 8.6 Hz, 6.7 Hz), 7.16–7.30 (m, 5H), 7.73 (d,
2H, J 5 9.3 Hz), 8.16 (d, 2H, J 5 9.3 Hz); 13C NMR (100.6
MHz, CD3OD) d 24.93 ppm, 31.03, 38.94, 47.44, 57.46, 60.87,
120.52, 125.68, 128.05, 129.57, 130.26, 137.70, 144.77, 145.59,
169.76, 172.02; mass spectrum (FAB1) myz 383 (MH1). Exact
mass calculated for C25H23N4O4 was 383.1719; found was
383.1720.
N-tert-butyloxycarbonyl)-L-a-hydroxyalanyl-L-prolyl-L-
phenylalanyl-p-nitroanilide (9). Compound 9 was prepared by
the procedure described for the preparation of Boc-Pro-Phe-
pNA using carboxylic acid 6 (0.615, 2.81 mmol), amine 8 (1.46,
2.95 mmol), HOBT (0.40 g, 2.95 mmol), diisopropylethylamine
(DIEA, 0.51 ml, 2.95 mmol), and EDC (0.646 g, 3.37 mmol) in
DMF (10 ml) to afford 1.59 g (97%) of a white solid: Rf 5 0.19
(1:2 hexaneyEtOAc); mp 144°C; 1H NMR (400 MHz, CDCl3)
d 0.80 ppm (d, 3H, J 5 6.9 Hz), 1.43 (s, 9H), 1.95–2.04 (m, 3H),
2.14–2.21 (m, 1H), 3.27 (d, 2H, J 5 13.7 Hz, 6.9 Hz), 3.43 (d,
1H, J 5 7.3 Hz), 3.71–3.77 (m, 3H), 4.39 (dd, 1H, J 5 7.2 Hz,
3.2 Hz), 4.43–4.47 (m, 1H), 4.78–4.86 (m, 2H), 6.80 (d, 1H, J 5
7.3 Hz), 7.18–7.33 (m, 5H), 7.77 (d, 2H, J 5 9.1 Hz), 8.17 (d,
2H, J 5 9.1 Hz), 8.68 (br s, 1H); 13C NMR (100.6 MHz, CDCl3)
d 13.75 ppm, 25.35, 28.33, 28.56, 36.64, 47.72, 48.20, 54.97,
61.73, 71.82, 79.96, 119.43, 124.83, 127.30, 128.90, 129.07,
136.36, 143.56, 143.62, 155.38, 169.34, 171.18, 173.04; mass
spectrum (FAB1) myz 584 (MH1). Exact mass calculated for
C29H38N5O8 was 584.2720; found was 584.2725.
N-(tert-butyloxycarbonyl)-L-alanyl-L-a-hydroxyalanyl-L-
prolyl-L-phenylalanyl-p-nitroanilide (10). Boc-peptide 9 (0.60 g,
3.16 mmol) was deprotected and subsequently coupled as
described above with N-(tert-butyloxycarbonyl)-L-alanine
(1.63 g, 2.72 mmol), HOBT (0.43 g, 3.16 mmol), DIEA (0.55
ml, 3.16 mmol), and EDC (0.66 g, 3.44 mmol) in DMF (10 ml).
Flash chromatography on silica gel using a gradient of 5:1
hexaneyEtOAc to EtOAc afforded peptide 10 (0.98 g, 55%) as
an off-white foam: mp 124°C (dec.); 1H NMR (400 MHz,
CDCl3) d 0.91 ppm (d, 3H, J 5 6.7 Hz), 1.33 (d, 3H, J 5 7.0
Hz), 1.44 (s, 9H), 1.90–1.99 (m, 3H), 2.09–2.15 (m, 1H),
3.17–3.35 (m, 2H), 3.60–3.80 (m, 3H), 4.00–4.50 (m, 2H),
4.34–4.46 (m, 4H), 4.74–4.84 (m, 1H), 5.12 (br s, 1H), 6.87 (br
s, 1H), 7.14–7.30 (m, 6H), 7.78 (d, 2H, J 5 8.2 Hz), 8.14 (d, 2H,
J 5 8.6 Hz), 9.03 (br s, 1H); 13C NMR (100.6 MHz, CDCl3) d
13.84 ppm, 17.99, 25.23, 28.24, 28.67, 36.71, 47.46, 47.75, 55.17,
60.37, 61.64, 71.42, 80.64, 119.43, 124.82, 127.22, 128.82,
129.12, 143.55, 143.72, 155.62, 169.59, 171.22, 172.97, 173.61;
mass spectrum (FAB1) myz 655 (MH1). Exact mass calculated
for C32H43N6O9 was 655.3092; found was 655.3106.
N-succinyl-L-alanyl-L-a-hydroxyalanyl-L-prolyl-L-phenylala-
nyl-p-nitroanilide (11). Peptide 10 (0.32 g, 0.48 mmol) was
deprotected by TFA and then coupled to succinic anhydride
(56.0 mg, 0.54 mmol), using DIEA (1.80 ml, 1.0 mmol) in DMF
(5 ml) to afford 0.28 g of crude product. The material was
purified by reversed-phase preparative HPLC (Dynamax
Chromosorb C18) using a gradient of 20–100% MeCN in
aqueous 0.1% TFA over 80 min at a flow rate of 9 mlymin. The
desired product was eluted as a single peak (detected at 320
nm) with a retention time of 30.2 min. The fractions were
collected and lyophilized to afford 173.2 mg (51%) of a white
solid: mp 122°C (dec.); 1H NMR (400 MHz, CD3OD) d 1.12
ppm (d, 3H, J 5 6.9 Hz), 1.33 (d, 3H, J 5 7.2 Hz), 1.74–1.83
(m, 1H), 1.85–1.99 (m, 2H), 2.09–2.17 (m, 1H), 2.41–2.69 (m,
4H), 3.11 (dd, 1H, J 5 13.7 Hz, 8.6 Hz), 3.22 (dd, 1H, J 5 13.7
Hz, 6.4 Hz), 3.66–3.80 (m, 2H), 4.13–4.18 (m, 1H), 4.28–4.40
(m, 3H), 4.69 (dd, 1H, J 5 8.6 Hz, 6.4 Hz), 7.15–7.25 (m, 5H),
7.86 (d, 2H, J 5 9.2 Hz), 8.17 (d, 2H, J 5 9.2 Hz); 13C NMR
(100.6 MHz, CD3OD) d 14.33 ppm, 14.56, 17.84, 17.88, 26.07,
29.99, 30.07, 30.25, 31.22, 31.34, 38.20, 50.59, 50.64, 57.03,
57.07, 62.24, 62.33, 72.66, 120.72, 125.61, 127.85, 129.50,
129.61, 130.22, 130.30, 138.29, 138.32, 144.70, 145.57, 172.13,
172.16, 173.40, 173.58, 174.22, 174.41, 174.66, 174.78, 175.19,
176.49; mass spectrum (FAB1) myz 655 (MH1). Exact mass
calculated for C31H39N6O10 was 655.2728; found was 655.2730.
N-succinyl-L-alanyl-L-a-ketoalanyl-L-prolyl-L-phenylalanyl-p-
nitroanilide (1). To a solution of oxalyl chloride (0.35 ml, 0.40
mmol) in methylene chloride (5.0 ml) at 278°C was added
dropwise a solution of freshly redistilled dimethyl sulfoxide
(DMSO) (0.43 ml, 6.0 mmol) in methylene chloride (1.2 ml).
After 10 min, a solution of a-hydroxy peptide 11 (132 mg, 0.20
mmol) in MeCN (2.0 ml, plus a 1-ml rinse) was added via
cannula under an atmosphere of nitrogen at a rate to maintain
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the internal temperature below 265°C. After 2.5 h, triethyl-
amine (1.2 ml) was added, allowing the mixture to warm up to
220°C. The reaction was quenched by the addition of cold
aqueous ammonium chloride solution. The aqueous layer was
extracted with methylene chloride (3 3 30 ml), and the organic
phases were combined and evaporated to afford 141.2 mg of
crude product. The material was further purified by HPLC as
for 11. The desired product was eluted with a retention time
of 26.4 min. The fractions were collected and lyophilized to
afford 89.5 mg (68%) of a white powder: mp 163°C; variable
temperature (20–110°C) 1H NMR experiments in DMF-d7
showed initial broadening and finally the coalescing of peaks,
suggesting the existence of rotamers. 1H NMR (400 MHz,
DMF-d7, 25°C, major rotamer) d 1.25 ppm (d, 1.5H, J 5 7.1
Hz), 1.29 (d, 1.5H, J 5 7.2 Hz), 1.31–1.34 (m, 1.5H), 1.42 (d,
1.5H, J 5 7.1 Hz), 1.68–1.75 (m, 0.5H), 1.79–1.95 (m, 2H),
1.98–2.45 (m, 1H), 2.45–2.63 (m, 3.5H), 3.05–3.19 (m, 1H),
3.28–3.38 (m, 1H), 3.43–3.55 (m, 1.5H), 3.59–3.71 (m, 1.5H),
4.30–4.40 (m, 0.5H), 4.41–4.53 (m, 1H), 4.60–4.69 (m, 0.5H),
4.75–4.87 (m, 1.5 H), 4.89–4.93 (m, 0.5H), 7.19–7.4 (m, 6H),
7.90–8.09 (m, 2H), 8.11 (dd, 1H, J 5 17.7 Hz, 7.0 Hz), 8.25 (t,
2H, J 5 8.7 Hz), 8.35–8.38 (m, 1H); 13C NMR (125.7 MHz,
DMF-d7, 25°C, major rotamer) d 14.42 ppm, 14.60, 18.01,
18.22, 26.45, 29.91, 30.27, 30.86, 31.31, 31.61, 38.20, 50.55,
50.79, 57.31, 57.52, 62.43, 62.81, 120.21, 125.63, 128.05, 129.58,
129.34, 130.30, 130.39, 138.27, 138.46, 144.77, 145.55, 172.11,
172.26, 173.44, 173.68, 174.21, 174.53, 174.86, 174.99, 175.14,
176.52, 206.35; mass spectrum (FAB1) myz 653 (MH1). Exact
mass calculated for C31H37N6O10 was 653.2571; found was
653.2571.
Hapten Analog (Inhibitor) Synthesis. L-deoxo-phenylalanyl-
p-nitroanilide (14). A solution of borane in THF (1.0 M, 24.8
ml) was cooled to 4°C and L-phenylalanine-p-nitroanilide (0.7
g, 2.5 mmol) was added in several batches. The resulting yellow
solution was heated to reflux for 2 h, then cooled to 4°C and
quenched by slow addition of a mixture of 50% MeOH
(volyvol) in THF until the solution stopped bubbling. The
solvent was evaporated, aqueous 1 N HCl (14 ml) and MeOH
(14 ml) were added, and the mixture was heated gently at 50°C.
After 1 h, the reaction mixture was neutralized with 1 N
NaOH, and then concentrated partially in vacuo. The aqueous
layer was extracted with EtOAc (4 3 200 ml), and the organic
layers were combined, dried, and concentrated to give 0.64 g
(96%) of a yellow oil: 1H NMR (400 MHz, DMSO-d6) d 2.57
ppm (dd, 1H, J 5 13.8 Hz, 7.2 Hz), 2.77 (dd, 1H, J 5 13.8 Hz,
5.2 Hz), 2.99–3.05 (m, 1H), 3.08–3.16 (m, 2H), 6.62 (d, 2H, J 5
9.3 Hz), 7.16–7.34 (m, 6H), 7.96 (d, 2H, J 5 9.2 Hz); 13C NMR
(100.6 MHz, DMSO-d6) d 41.03 ppm, 48.57, 51.77, 110.85,
126.07, 126.18, 128.26, 129.21, 135.58, 139.14, 154.70; mass
spectrum (FAB1) myz 272 (MH1). Exact mass calculated for
C15H18N3O2 was 272.1399; found was 272.1396.
N-(tert-butyloxycarbonyl)-L-alanyl-L-a-hydroxyalanyl-L-
prolyl-L-deoxo-phenylalanyl-p-nitroanilide (16). Compound 14
(0.62 g, 2.3 mmol) was coupled with N-(tert-butyloxycarbonyl)-
L-proline (0.52g, 2.40 mmol), HOBT (0.32 g, 2.4 mmol), and
EDC (0.52, 2.7 mmol) in DMF (10 ml). The resultant product
was purified by flash chromatography on silica gel to afford
1.0 g of a yellow solid, which was treated with TFA to give
0.98 g of the desired salt (15). Compound 15 (0.52 g, 1.1 mmol)
then was reacted with 6 (0.23 g, 1.0 mmol), HOBT (0.15 g, 1.1
mmol), DIEA (0.19 ml, 1.1 mmol), and EDC (0.24 g, 1.2 mmol)
in DMF (5 ml). After silica gel chromatography in 1:3 hexaney
EtOAc, 0.53 g (91%) of a yellow foam was obtained: Rf 5 0.10
(1:2 hexaneyEtOAc); 1H NMR (400 MHz, CDCl3, major
rotamer at 25°C) d 1.02 ppm (d, 2.16H, J 5 6.8 Hz), 1.07 (d,
0.85H, J 5 6.8 Hz), 1.41, 1.44 (2s, 9H), 1.66–1.76 (m, 1H),
1.84–2.15 (m, 3H), 2.90–2.94 (m, 2H), 3.24–3.40 (m, 2H),
3.72–3.75 (m, 2H), 3.85–3.95 (m, 1H), 4.19–4.32 (m, 2H), 4.39
(d, 1H, J 5 3.8 Hz), 6.59–6.64 (m, 2H), 7.18–7.29 (m, 5H),
7.97–8.02 (m, 2H); 13C NMR (125.7 MHz, CDCl3) d 14.14
ppm, 25.30, 28.16, 28.33, 31.37, 36.41, 38.42, 46.28, 47.64, 48.17,
50.57, 61.46, 71.69, 79.76, 111.08, 126.30, 126.94, 128.74,
129.97, 137.08, 137.73, 153,47, 155.37, 162.50, 171.49, 172.51;
mass spectrum (FAB1) myz 570 (MH1). Exact mass calculated
for C29H40N5O7 was 570.2928; found was 570.2920.
N-Acetyl-L-alanyl-L-a-ketoalanyl-L-prolyl-L-deoxo-phenylala-
nyl-p-nitroanilide (13). Boc-protected 16 (0.51 g, 0.9 mmol) was
treated with TFA to give 0.38 g (92%) of the trif luoroacetate
salt as a yellow foam, which was coupled with N-acetyl-L-
alanine (143.0 mg, 1.1 mmol), HOBT (148.0 mg, 1.1 mmol),
triethylamine (TEA, 0.25 ml), and EDC (230 mg, 1.2 mmol) to
afford 0.5 g of crude product as a yellow solid. The material was
purified by preparative HPLC to give 336 mg (53%) of a yellow
powder. Freshly distilled pyridine (50 mL) and Dess-Martin
periodinane (170 mg, 0.40 mmol) were added to a solution of
this material (182 mg, 0.31 mmol) in methylene chloride (4 ml).
After 1.5 h at room temperature, the reaction was cooled to
0°C and stopped by the addition of saturated sodium sulfite (5
ml). After being stirred for 5 min at 0°C, the reaction mixture
was extracted with methylene chloride (4 3 40 ml). The
organic layers were combined, dried, and evaporated in vacuo.
The residue was purified by preparative HPLC to give 149 mg
(82%) of the desired product as a yellow powder: mp 163–
165°C; UV (MeOH) 210 nm (« 10, 500), 382 (12,000); 1H NMR
(400 MHz, DMSO-d6, major rotamer at 25°C) d 1.09–1.18 ppm
(m, 4.5H), 1.32 (d, 1.5H, J 5 7.1 Hz), 1.57–1.98 (m, 4H), 1.78
(s, 1.5H), 1.80 (s, 1.5H), 2.71–2.86 (m, 2H), 3.15–3.24 (m, 2H),
3.25–3.60 (m, 2H), 4.02–4.35 (m, 2H), 4.42–4.55 (m, 1H),
4.57–4.80 (m, 1H), 6.63–6.67 (m, 2H), 7.15–7.30 (m, 5H),
7.98–8.03 (m, 2H); mass spectrum (FAB1) myz 583 (MH1).
Exact mass calculated for C29H39N6O7 was 583.2881; found
was 583.2881.
Protein-Hapten Conjugates. Protein-hapten conjugates
were prepared as previously described (27). The epitope
densities were determined by comparing the UV difference
spectra of the conjugated and the unconjugated proteins at 320
nm (BSA conjugate, «hapten 5 10,560) and 316 nm [keyhole
limpet hemocyanin (KLH) conjugate, «hapten 5 10,440].
Epitope densities of 8.1 and 6.7 were measured for the BSA
and KLH conjugates, respectively.
Peptide Isomerization Assays. These assays were performed
by the described method (28) at 0°C in 50 mM Hepesy50 mM
NaCl, pH 7.8 buffer containing 2% trif luoroethanol (TFE) in
the presence of antibody 47 Mar.1 (7 mM) or absence of
antibody. A buffer solution containing antibody and a-chymo-
trypsin (40 ml of 60 mgyml solution in 1 mM HCl) was
incubated for 10 min at 0°C in a 0.4-ml cuvette. Substrate (8 ml
of 6.25–250 mM stock solutions in anhydrous TFE containing
470 mM LiCl; cisytrans 5 60:40) was rapidly added, and the
reaction progress curves [with cis-(2) in the range of 0.125–3
mM] were recorded spectrophotometrically by measuring the
absorbance increase at 460 nm (« 270) as a function of time
(over 10 min, 150 data pointsymin). The absorbance data
points then were transferred to a Macintosh computer, con-
verted to [time (min), OD460] pairs, and saved as a raw data file
by using KALEIDAGRAPH. These data were fitted to an inte-
grated rate equation (including terms for both the catalyzed
and uncatalyzed isomerization rates) derived by Kofron et al.
(28) for the calculation of kcat and Km values, using the DYNAFIT
software package (ref. 29; for more information about DY-
NAFIT, see: http:yywww.biokin.com) running on a power
Macintosh. See Fig. 2 for initial reaction velocities calculated
from this program versus substrate concentrations. Inhibition
experiments were measured at two substrate concentrations
(0.6 mM and 0.3 mM of cis-2) with inhibitor (13) concentra-
tions in the range of 5–15 mM (see Fig. 4). The Ki value (3.0 6
0.4 mM) was calculated by using nonlinear least-squares opti-
mization to a competitive equation as described (28), using
DYNAFIT.
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Protein Folding Assays. RNase T1 from Aspergillus oryzae
was purchased from Boehringer Mannheim, purified by ion
exchange chromatography (Mono Q), and dialysed into dis-
tilled water at 4°C. The protein concentration was determined
by absorbance (A280 5 1.9 OD for 1 mgyml of RNase T1) (30),
and the sample solution then was quantitatively divided into
small vials for lyophilization to dryness. RNase T1 was dena-
tured by incubation in 8 M urea, 0.1 M TriszHCl, 1 mM EDTA,
pH 8.0 at 25°C for 2 h. Refolding was initiated by diluting 10
ml of unfolded protein with 390 ml of 0.1 M TriszHCl, 1 mM
EDTA, pH 8.0, containing the appropriate concentrations of
the antibody, hapten 1, and hapten-analog 13 in a 0.4-ml
fluorimeter cell at 10°C. The final concentrations for refolding
reactions were 3.0 mM RNase T1 in 0.2 M urea, 0.1 M TriszHCl,
1 mM EDTA, pH 8.0 at 10 6 0.1°C. The refolding reaction was
monitored by the increase in fluorescence at 320 nm (5 nm slit)
after excitation at 268 nm (1 nm slit) using a Hitachi F-4500
fluorescence spectrophotometer. The excitation shutter was
closed between the individual measurements to minimize
radiation damage during the kinetic experiments (31). All data
were reproducible with deviations of less than 3.5%.
RESULTS AND DISCUSSION
Hapten Synthesis and Antibody Production. To facilitate
kinetic comparisons to the natural enzymes, hapten 1 (Fig. 1)
was designed to mimic the peptide succinyl-L-alanyl-L-alanyl-
L-prolyl-L-phenylalanyl-p-nitroaniline (Suc-Ala-Ala-Pro-Phe-
pNA) (2), a commercially available substrate for kinetic and
mechanistic studies of cyclophilins and FKBP. The peptide
Suc-Ala-Ala-Pro-Phe-pNA undergoes spontaneous cis to trans
isomerization at 37°C with a first-order rate constant of
approximately 0.15 s21 (18), a relatively low background rate
for small peptides. Synthesis of hapten 1 was carried out from
the hydroxy-acid precursor (6) by standard peptide coupling
protocols (32) as shown in Fig. 1. Hydroxy-acid 6 was prepared
in five steps from oxazolidinone 3. Treatment of (4S,5R)-(2)-
4-methyl-5-phenyl-2-oxazolidinone with Boc-anhydride and
triethylamine afforded the N-Boc oxazolidinone (97%), which
subsequently was oxidized with ruthenium trichloride
(RuCl3z3H2O) and sodium periodate to give acid 4 (48%).
Quantitative conversion of the acid to its methyl ester (5) was
accomplished by treatment with diazomethane. The resultant
oxazolidinone (5) was selectively ring-opened with powdered
cesium carbonate in methanol to give the methyl ester (54%),
which was saponified to provide the desired hydroxy-acid (6)
in 91% yield. Carbodiimide-mediated coupling of N-Boc-L-
proline with L-Phe-p-nitroaniline (7) in DMF gave the Boc-
protected dipeptide (89%). Acidolytic deprotection of the Boc
group using TFA provided amine 8 in 98% yield as a trif lu-
oroacetate salt. Tripeptide 9 was generated by coupling amine
8 with hydroxy-acid 6 in DMF (97%). Treatment with TFA
afforded the amine-TFA salt, which was coupled with N-Boc-
alanine as described above, to give the Boc-tetrapeptide (10)
in 55% yield. Again, the N-terminal Boc group was depro-
tected by using TFA, and the resultant amine-TFA salt was
acylated with succinic anhydride in the presence of DIEA. The
hydroxy-peptide (11) was isolated in 51% yield after purifica-
tion by reversed-phase HPLC. Swern oxidation of the alcohol
moiety followed by further HPLC separation provided hapten
1 in 68% yield.
Antibodies specific for hapten 1 were produced by standard
methods using BALByc mice immunized with the keyhole
limpet hemocyanin conjugate of 1 (27). ELISA assays with the
BSA conjugate of 1 identified more than 100 monoclonal cell
lines expressing antibody specific for 1. Ascites fluid generated
from the cell lines was purified by protein G affinity chroma-
tography. A total of 67 antibodies were found by ELISA assays
to bind both free hapten 1 and substrate 2. Antibodies were
judged to be greater than 95% pure by SDSyPAGE.
Catalytic Assays and Kinetic Characterization. The most
widely used method to assay peptidyl-prolyl cis-trans isomer-
ization is an enzyme-coupled assay that depends on the
inability of a-chymotrypsin to hydrolyze Suc-Ala-Xaa-Pro-
Phe-pNA when the Xaa-Pro bond is in the cis conformation
(28). Although a direct f luorimetric assay (33) has been
developed, the substrate scope is narrow, and the low substrate
concentrations used in the fluorimetric assay may limit its
application to antibody-catalyzed reactions. Reliable methods
for analyzing the kinetics by NMR spectroscopy recently have
been reported (34, 35); however, these methods are not
convenient for screening large numbers of antibodies. By using
the enzyme-coupled assay, three antibodies were identified
that catalyzed the isomerization reaction of substrate 2. One
catalyst (47 Mar.1) was further purified by ion exchange (Mono
S) chromatography and characterized in detail.
The apparent first-order rate constants and kinetic param-
eters for both the uncatalyzed and antibody-catalyzed reac-
tions were derived by analysis of the progress curves by using
the computer program DYNAFIT (29). The background rate of
cis to trans isomerization of substrate 2 at 0°C was measured
to be 0.0024 s21 in 50 mM Hepesy50 mM NaCl, pH 7.8 buffer
containing 2% TFE and 9.4 mM LiCl (LiCl-TFE mixture
results in increased concentration of the cis substrate, simpli-
fying kinetic analysis). Antibody 47 Mar.1 exhibited Michaelis-
Menten behavior with kcat 5 1.58 s21, Km 5 1.79 mM, and
kcatyKm 5 883 s21zM21 for the cis substrate (cis-2) (Fig. 2). For
comparison, the cis to trans isomerization reactions of sub-
strate 2 catalyzed by the natural enzymes cyclophilin (from calf
thymus, Sigma) and FKBP (from recombinant human, Sigma)
have kcatyKm values of 1.2 3 107 s21zM21, and 6.4 3 105
FIG. 1. Synthesis of hapten 1. Conditions: (a) (Boc)2O, triethyl-
amine,97%; (b) RuCl3yNaIO4, 48%; (c) CH2N2, 100%; (d) Cs2CO3,
54%; (e) 1N NaOH, 91%; ( f ) Boc-ProyDIEAyHOBT, EDC, 0°C 3
room temperature (RT), 89%; (g) TFA, 0°C, 98%; (h) DIEAyHOBT;
(i) 1 6, EDC, 0°C 3 RT, 97%; (j) TFA, 0°C, 100%; (k) Boc-Alay
DIEAyHOBT, EDC, 0°C 3 RT, 55%; (l) TFA, 0°C, 100%; (m)
Succinic anhydrideyDIEA, 51%; (n) (COCl)2, DMSO, 278°C 3
220°C, 68%.
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s21zM21, respectively. Under similar assay conditions, these
kinetic data and the background rate of 2 are in good
accordance with previously determined values (28).
To verify that catalysis is occurring in the antibody combin-
ing site, hapten inhibition studies were carried out. However,
the results were difficult to interpret because of hydrolysis of
hapten 1 by chymotrypsin. Attempts to inhibit catalysis using
a portion of the hapten epitope (12) were unsuccessful. A
nonhydrolyzable analog (13) of the hapten (1) therefore was
synthesized that contains an aminomethylene isostere in place
of the susceptible p-nitroaniline bond (Fig. 3). The amide bond
of L-Phe-p-nitroaniline was selectively reduced by using bo-
rane-THF; acidic work-up with aqueous HCl led to the
isolation of diamine 14 in 96% yield. Coupling of this amine
with Boc-proline followed by acidolytic deprotection with TFA
afforded dipeptide 15 as a TFA salt in 95% yield. Further
coupling of 15 with hydroxy-acid 6 gave a 91% yield of product
16. Another round of TFA deprotection (92%) and coupling
(53%) with N-acetyl-L-alanine afforded 17, which was oxidized
by Dess-Martin periodinane. After final purification by pre-
parative HPLC, the desired hapten analog (13) was obtained
in 82% yield.
Hapten analog 13 was found to inhibit the catalytic activity
of antibody 47 Mar.1 (Fig. 4). Least-squares Dixon analysis
with two sets of substrate concentrations (0.6 mM and 0.3 mM
of cis-2) afforded a Ki value of 3.0 6 0.4 mM. This result
indicates that catalysis is associated with the antibody com-
bining site. Not surprisingly, hapten analog 13 is also a good
inhibitor for the cis-trans isomerization reactions of 2 catalyzed
by cyclophilin (Ki 5 14 mM) and FKBP (Ki 5 11 mM). The rate
acceleration of this catalytic antibody (kcatykuncat 5 658) is very
close to the value of KmyKi (746), consistent with preferential
stabilization of the transition state by the antibody. The
antibody-catalyzed reaction is insensitive to pH variations, and
no solvent deuterium isotope effect is observed (28). These
findings, as with the natural rotamases, suggest the lack of
involvement of catalytic groups in the antibody-substrate
complex. Therefore it is likely the a-keto amide functional
group in hapten 1 is acting as a mimic of a conformationally
distorted transition state rather than as an electrophile to elicit
a nucleophile in the antibody binding site.
Antibody-Catalyzed Protein Folding. The natural protein,
RNase T1, then was examined as a possible substrate for the
antibody. RNase T1 is a small protein (104 amino acids) with
four prolyl peptide bonds (36) that has been widely used as a
model protein for folding studies of the natural rotamases,
cyclophilins (37), and FKBP (38). The unfolding of RNase T1
by urea or guanidine hydrochloride is a completely reversible
reaction, and the refolding experiments can be carried out by
monitoring the fluorescence enhancement of the sole trypto-
phan residue, which is completely buried in the folded protein
(37). In the absence of an isomerase, the refolding reaction is
approximately first-order at early time and complete after 65
min at 10°C, consistent with the model that refolding is roughly
a sum of two phases, an intermediate phase with a time
constant, t ' 400 s, and a very slow phase with t ' 3,000 s (4).
Antibody 47 Mar.1 (6.4 mM) leads to a 4- to 5-fold increase in
the folding rate of RNase T1 (Fig. 5). Furthermore, the
antibody-catalyzed reaction is completely inhibited by the
addition of 9.1 mM hapten 1 or by 10.6 mM hapten analog 13,
again demonstrating that the folding reaction is associated with
the antibody combining site. Additionally, several other anti-
bodies elicited against hapten 1 have been examined, and none
of them catalyze the folding reaction. For comparison, FKBP
FIG. 2. Plot of reaction velocity versus substrate concentration for
the cis to trans isomerization reaction of 2. Initial velocities were
calculated from progress curves measured at 0°C in 50 mM Hepesy50
mM NaCl, pH 7.8 buffer containing 2% TFE, in the presence of 7.0
mM antibody 47 Mar.1 (n) and in the absence of a catalyst (F). (Inset)
The corresponding Lineweaver–Burk plot for the antibody-catalyzed
isomerization reaction.
FIG. 3. Synthesis of hapten analog (inhibitor) 13 and the structure
of 12. Conditions: (a) BH3zTHF; (b) aqueous HCl, 96% in two steps;
(c) Boc-ProyEDCyHOBT, 0°C 3 room temperature (RT), 94%; (d)
TFA, 0°C, 96%; (e) DIEAyHOBT, 0°C; ( f ) 1 6, EDC, 0°C, 91% in two
steps; (g) TFA, 0°C, 92%; (h) N-acetyl-AlayDIEAyHOBT, EDC, 0°C
3 RT, 53%; (i) Dess-Martin periodinane, 278°C, 82%.
FIG. 4. V0 vs. [I] plot for antibody 47 Mar.1 catalyzed cis to trans
isomerization reaction of 2 in the presence of inhibitor 13. Antibody
concentration was 7.0 mM. Initial velocities were obtained by the same
methods as described in Fig. 2 at two concentrations of substrate 2: 1
mM [cis-(2) 5 0.6 mM] (F) and 0.5 mM [cis-(2) 5 0.3 mM] (n).
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(0.14 mM) increases the rate of RNase T1 folding 7- to 8-fold
over the background reaction under the same assay conditions.
However, unlike the antibody, catalysis by FKBP is not inhib-
ited by hapten 1 or analog 13 at concentrations up to 150 mM.
The refolding of RNase T1 catalyzed by the antibody is more
complicated and less efficient than isomerization of the relative
small, unstructured peptide. Several exponential phases and
intermediates (4) are involved during the folding pathway from
the denatured to the native state, making it difficult to charac-
terize in detail the peptidyl-prolyl bond isomerization reaction(s).
Spontaneous refolding of RNase T1 chains (with four prolyl
residues: Ser-37–Tyr-38–Pro-39–His-40, Ser-53–Ser-54–Pro-55–
Tyr-56, Glu-58–Trp-59–Pro-60–Ile-61, and Gly-71–Ser-72–Pro-
73–Gly-74) presumably is determined by the slow trans [3 cis
isomerization of the Tyr-38–Pro-39 and Ser-54–Pro-55 peptide
bonds, which are both cis in the native state, but are predomi-
nantly (80–90%) trans in the unfolded protein (4)]. However,
catalysis of isomerization at Pro-55 by natural rotamases may be
the main contributor for the acceleration of RNase T1 folding
because this proline, unlike Pro-39, which is buried in the native
protein and also presumably in folding intermediates, is solvent-
exposed (39). The ability of antibody 47 Mar.1 to catalyze folding
of RNase T1 suggests that the antibody has relatively broad
substrate specificity. This may result from the uncharged hydro-
phobic nature of the hapten. The reduced rate of the antibody-
catalyzed reaction compared with FKBP and cyclophilins sug-
gests that the antibody may distort the amide bond but may not
effectively catalyze the bond rotation reaction. In this regard,
spirocyclic ring systems may be more efficient analogs than a-keto
amide moieties for mimicking an orthogonal transition state.
Nevertheless, this study and that of Yli-Kauhaluoma et al. (26)
suggest that the use of distorted substrate analogs is a reproduc-
ible means for generating prolyl isomerization catalysts. Similar
approaches have been used to generate antibodies that catalyze
the isomerization of carbon-carbon sigma bonds in bridged
biphenyls (40). Finally, the demonstration that antibodies can
catalyze conformational changes involving the protein backbone
raises the possibility that antibodies also can be generated that
catalyze other conformational changes such as those involved in
signal transduction processes, either in vitro or in vivo.
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FIG. 5. Catalysis of RNase T1 refolding reaction by antibody 47
Mar.1. The change in fluorescence at 320 nm is shown as a function
of the time. The final conditions for refolding were 3.0 mM RNase T1
in 0.2 M urea, 0.1 M TriszHCl, 1 mM EDTA, pH 8.0 at 10 6 0.1°C.
Uncatalyzed folding reaction in the absence of a catalyst (); folding
reactions in the presence of 6.4 mM antibody 47 Mar.1 (), 6.4 mM
antibody, and an additional hapten 1: 3.7 mM ({) and 9.1 mM (E), and
0.14 mM FKBP (F).
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